Format

Send to

Choose Destination
Postgrad Med. 2014 Mar;126(2):110-6. doi: 10.3810/pgm.2014.03.2746.

Combination phentermine/topiramate for obesity treatment in primary care: a review.

Author information

1
Departments of Psychiatry and Medicine, University of California at Davis, School of Medicine, Davis, CA.

Abstract

The treatment of obesity is often met with a myriad of challenges in the primary care setting. Nevertheless, a modest 5% weight loss is considered clinically significant and may be associated with health benefits. Phentermine/topiramate (Qsymia), available in the United States since September 2012, achieves clinically meaningful weight loss along with improvements in weight-related comorbidities. This combination drug therapy could be an additional tool for primary care providers in their quest for effective management of obesity. Special precautions and close monitoring are indicated when prescribing phentermine/topiramate for women of childbearing potential. Monitoring of heart rate and psychiatric and cognitive side effects is important.

PMID:
24685974
DOI:
10.3810/pgm.2014.03.2746
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center